The Danish firm anticipates to be able to existing information from 2 various other researches later on in 2026.
发布者：BY MARKETWIRE，转转请注明出处：https://robotalks.cn/genmab-shows-promising-results-again-with-cancer-drug-in-new-phase-3-study-2/
Genmab shows promising results again with cancer drug in new Phase 3 study
赞 (0)
关于作者
EMA lags behind FDA in new drugs, but overall activity level is close to record high
上一篇
20 1 月, 2026
European allies work on response to Trump’s tariff threat
下一篇
20 1 月, 2026
相关推荐
-
Identiv Welcomes Kim Macaulay as New Senior Vice President of Sales, Marketing, and Business Development
SANTA ANA, Calif.–( ORGANIZATION CABLE)– Identiv, Inc. (NASDAQ: INVE), an international leader in RFID and BLE-enabled Net of Points (IoT) remedies, today introduced th…
-
The state of social media marketing for publishers | Trends and tactics shaping paid social
This State of the Market Record, created in collaboration with Piano, discovers just how authors involve with social networks, particularly paid social networks, what methods they …
-
The age-old problem of long-term care
Caring well for the senior is an acquainted difficulty. Some senior individuals require close clinical interest in centers; others deal with minimized capacities while not intendin…
-
New Nvidia Blackwell chip for China may outpace H20 model
Nvidia is servicing a brand-new AI chip for China that can be more powerful than the H20 design it presently markets there, according to individuals aware of the strategies, Reuter…
-
OnRobot to Showcase Effortless Automation Deployment Through D:PLOY Platform at Automate 2025
Visitors at the Automate show in Detroit will experience the benefits of OnRobot’s One System Solution: seamless integration of the company’s end-of-arm-tooling across all major ro…
